ClinicalTrials.gg

Program

SKB571

A development code. Also written as “SKB571 for injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Digestive System Neoplasms · Pancreatic Neoplasms · Squamous Cell Carcinoma of Head and Neck · Lung Neoplasms, led by Sichuan Kelun Pharmaceutical.

Furthest: phase 2, since Nov 13, 20257 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceutical77 open or runningphase 2since Nov 13, 2025Nov 28, 2024Dec 2026phase 1 · NCT06725381

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 28, 2024First study: phase 1 study in Solid MalignanciesFirst studyNCT06725381 · 138 planned · China
  2. Nov 13, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07230405 · 295 planned · China
  3. Dec 15, 2025Phase 2 study in Non-small Lung CancerNCT07308106 · 70 planned · China
  4. Apr 14, 2026Phase 2 study in Digestive System NeoplasmsNCT07564466 · 160 planned · China
  5. May 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07622186 · 150 planned · China
  6. Jun 16, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07668154 · 120 planned · China
  7. Sep 2, 2026Phase 2 study in Pancreatic NeoplasmsNCT07814066 · 30 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Solid MalignanciesNCT06725381
  2. Jun 30, 2027Primary completion: phase 2 study in Non-small Lung CancerNCT07308106
  3. Aug 31, 2027Primary completion: phase 2 study in Digestive System NeoplasmsNCT07564466
  4. Jan 19, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07230405

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07814066Pancreatic Neoplasms2Not yet recruitingFeb 28, 202830
NCT07668154Squamous Cell Carcinoma of Head and Neck · China2RecruitingSep 30, 2028120
NCT07622186Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 31, 2028150
NCT07564466Digestive System Neoplasms · China2RecruitingAug 31, 2027160
NCT07308106Non-small Lung Cancer · China2RecruitingJun 30, 202770
NCT07230405Carcinoma, Non-Small-Cell Lung · China2RecruitingJan 19, 2028295
NCT06725381Solid Malignancies · China1RecruitingDec 2026138

How it is read

Names in the registry

  • “SKB571 for injection”, 4 entries
  • “SKB571”, 3 entries

Codes read as this program: SKB571.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.